Abstract
We have carried out laboratory and clinical studies on cefteram pivoxil (CFTM-PI, T-2588).
The results are summarized as follows.
CFTM-PI was given through oral administration to 2 children each at dose levels of 1.5mg/kg, 3mg/kg and 6mg/kg. After administration, mean peak serum levels of CFTM obtained for the 3 dose levels were 0.66±0.01μg/ml, 1.26±1.05μg/ml and 2.28±0.95μg/ml at 2 hours, respectively, and mean half-lives were 1.07±0.52 hours, 1.32±0.76 hours and 2.53±1.70 hours, respectively.
Mean urinary excretion rates of CFTM were 19.0±4.0%, 9.4±1.5% and 19.9±4.0% in the first 8 hours after administration of 1.5mg/kg, 3mg/kg, 6mg/kg, respectively.
Treatment with CFTM-PI was made in 36 cases of pediatric bacterial infections including 20 cases of tonsillitis, 3 cases of bronchitis, 6 cases of scarlet fever, 3 cases of UTI and 1 case each of bronchopneumonia, abscess, staphylococcal scalded skin syndrome and vaginitis.
Results obtained were excellent in 22 cases, good in 14 cases.
No significant side effect due to the drug was observed in any cases.
